GO:1900016 negative regulation of cytokine production involved in inflammatory response: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900016 describes any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production specifically involved in the inflammatory response.
• This negative regulation is essential to prevent excessive inflammation and tissue damage, and its dysregulation contributes to chronic inflammatory and autoimmune diseases.
• Key molecular players include anti-inflammatory cytokines such as IL-37, metabolic regulators like itaconate via KEAP1/Nrf2, and negative regulators of inflammasome activation.
• Post-translational modifications, including S-persulfidation, can protect macrophages from oxidative-inflammatory stress and modulate cytokine output.
• Cell-surface receptors such as IL-1R2 and CD44c act as inhibitory regulators of cytokine production in inflammatory settings.
• Understanding GO:1900016 provides a framework for developing therapies that dampen pathological inflammation without compromising host defense.
Description
The inflammatory response is a double-edged sword: it is required for host defense, but when cytokine production is not properly restrained, it can cause chronic tissue damage and disease. The Gene Ontology term GO:1900016, negative regulation of cytokine production involved in inflammatory response, captures the biological processes that actively stop, prevent, or reduce the production of cytokines specifically during inflammation. This term is distinct from general negative regulation of cytokine production because it is restricted to the context of the inflammatory response, making it highly relevant for immunology and pathology research. Researchers studying diseases such as periodontitis, asthma, and autoinflammatory disorders need to understand how this negative regulation is achieved and how it fails. The QuickGO definition provides a precise scope: any process that stops, prevents or reduces the frequency, rate or extent of cytokine production involved in inflammatory response. This article synthesizes published findings on the mechanisms, key genes, and experimental models used to study this critical regulatory process.
negative regulation of cytokine production involved in inflammatory response At A Glance
| GO ID | GO:1900016 |
|---|---|
| GO term | negative regulation of cytokine production involved in inflammatory response |
| Ontology | biological_process |
| Synonym | down regulation of cytokine production involved in acute inflammatory response; down regulation of cytokine production involved in inflammatory response; negative regulation of cytokine production involved in acute inflammatory response |
| Major function | Restrains the production of cytokines during inflammation to prevent excessive tissue damage and maintain homeostasis. |
| Key regulators | Anti-inflammatory cytokines (e.g., IL-37), metabolic sensors (e.g., KEAP1/Nrf2), inhibitory receptors (e.g., IL-1R2, CD44c), and inflammasome inhibitors. |
| Associated diseases | Chronic inflammatory diseases, periodontitis, asthma, autoimmune disorders, and cytokine storms. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, cytokine profiling, and macrophage activation assays. |
What Is GO:1900016?
GO:1900016 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production involved in inflammatory response. In simpler terms, it encompasses all molecular and cellular events that put the brakes on the production of inflammatory cytokines, thereby limiting or resolving inflammation. This includes negative regulation at transcriptional, post-transcriptional, and post-translational levels, as well as through anti-inflammatory metabolites and receptors.
Why Is negative regulation of cytokine production involved in inflammatory response Important in Cell Biology?
GO:1900016 is critically important because uncontrolled cytokine production drives a wide range of acute and chronic inflammatory diseases, from periodontitis to asthma and systemic inflammatory syndromes. Understanding the negative regulatory mechanisms allows researchers to identify therapeutic targets that can dampen pathological inflammation without fully suppressing immune responses. Moreover, this term is a hub for integrating metabolic, transcriptional, and post-translational control of immunity, as exemplified by itaconate-mediated Nrf2 activation and S-persulfidation in macrophages.
• Prevents cytokine storms and excessive tissue damage during infection.
• Maintains immune homeostasis by balancing pro- and anti-inflammatory signals.
• Dysregulation is linked to chronic inflammatory diseases such as periodontitis and asthma.
• Provides targets for anti-inflammatory drug development, including IL-37 and itaconate derivatives.
• Involves metabolic reprogramming that links cellular metabolism to immune regulation.
• Inhibitory receptors like IL-1R2 and CD44c fine-tune cytokine output in teleost and mammalian models.
• Negative regulators of inflammasomes are essential to prevent autoinflammatory disorders.
• Understanding species-specific mechanisms can inform comparative immunology and aquaculture.
• CRISPR screens can identify novel negative regulators within this GO term.
• Biomarkers of negative regulation may predict disease severity and treatment response.
What Happens During negative regulation of cytokine production involved in inflammatory response?
Initiation of negative feedback by anti-inflammatory cytokines
In simple terms: Anti-inflammatory cytokines act like brakes that tell immune cells to stop making inflammatory signals.
Upon inflammation, anti-inflammatory cytokines such as IL-37 are produced and bind to their receptors, triggering signaling cascades that suppress the transcription and translation of pro-inflammatory cytokines. This negative feedback loop is essential to prevent runaway inflammation and is a core component of GO:1900016.
Metabolic regulation via itaconate and KEAP1/Nrf2
In simple terms: Certain metabolic byproducts can chemically modify proteins to turn down inflammation.
Itaconate, a metabolite produced by activated macrophages, alkylates KEAP1, leading to Nrf2 activation and subsequent suppression of pro-inflammatory cytokine production. This represents a metabolic checkpoint that negatively regulates cytokine production involved in inflammatory response, linking cellular metabolism to immune suppression.
Post-translational modifications: S-persulfidation
In simple terms: Adding sulfur atoms to proteins can protect cells and reduce inflammatory cytokine release.
Widespread S-persulfidation occurs in activated macrophages as a protective mechanism against oxidative-inflammatory stress, and this modification is associated with reduced production of inflammatory cytokines. This highlights a redox-based negative regulatory mechanism within GO:1900016.
Inhibitory receptors and decoy receptors
In simple terms: Decoy receptors soak up inflammatory signals or directly inhibit cells to stop cytokine production.
The type 2 interleukin-1 receptor (IL-1R2) acts as an inhibitory regulator of trained immunity in teleost, dampening cytokine production during inflammatory challenges. Similarly, piscine CD44c negatively regulates cytokine production in viral and bacterial infection. These receptor-mediated mechanisms are key to GO:1900016.
Inflammasome inhibition
In simple terms: Blocking the inflammasome machine prevents the release of powerful inflammatory cytokines.
Negative regulation of the inflammasome is a critical layer of control that keeps inflammation under check by reducing the production of IL-1β and IL-18. This process directly falls under GO:1900016 and involves multiple inhibitors that act at the level of inflammasome assembly and activity.
Key Genes Involved in GO:1900016 negative regulation of cytokine production involved in inflammatory response
The following genes and proteins are experimentally validated participants in the negative regulation of cytokine production involved in inflammatory response (GO:1900016).
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL37 | Anti-inflammatory cytokine that suppresses pro-inflammatory cytokine production | Therapeutic potential in asthma and other inflammatory diseases |
| KEAP1 | Substrate adaptor for Nrf2 degradation; alkylated by itaconate to activate Nrf2 | Metabolic control of inflammation; target for anti-inflammatory drugs |
| NFE2L2 (Nrf2) | Transcription factor that induces antioxidant and anti-inflammatory genes | Mediates itaconate's negative regulation of cytokine production |
| IL1R2 | Decoy receptor for IL-1 that inhibits trained immunity | Inhibitory regulator of cytokine production in teleost |
| CD44c | Cell surface receptor that negatively regulates cytokine production | Viral and bacterial infection models; comparative immunology |
| NLRP3 | Inflammasome sensor; its inhibition reduces IL-1β/IL-18 production | Target for anti-inflammatory therapies; negative regulation keeps it in check |
| CASP1 | Inflammasome effector caspase; inhibition reduces cytokine maturation | Key node in negative regulation of inflammasome-dependent cytokines |
| GSDMD | Pore-forming protein downstream of inflammasomes; its regulation limits cytokine release | Potential target to block pyroptosis and cytokine storm |
| SOCS1 | Cytokine signaling suppressor; inhibits JAK-STAT-driven cytokine production | Negative feedback regulator of inflammation |
| SOCS3 | Suppressor of cytokine signaling; dampens IL-6 and other cytokine signals | Important in resolving inflammation |
| A20 (TNFAIP3) | Ubiquitin-editing enzyme that inhibits NF-κB and cytokine production | Critical negative regulator; mutations cause autoinflammatory disease |
| IRAK-M | Kinase-dead IRAK family member that negatively regulates TLR signaling | Limits cytokine production in macrophages |
| SHIP1 | Inositol phosphatase that inhibits PI3K/Akt signaling and cytokine production | Negative regulator in immune cells |
| PD-L1 | Immune checkpoint ligand that can suppress cytokine production | Relevance in cancer immunology and inflammation |
| IL-10 | Anti-inflammatory cytokine that broadly suppresses pro-inflammatory cytokine production | Central negative regulator of inflammation |
| TGF-β | Anti-inflammatory cytokine that inhibits cytokine production in multiple cell types | Key mediator of immune suppression |
| IL-1RA | Natural antagonist of IL-1 receptor; reduces IL-1-driven cytokine production | Therapeutic protein for autoinflammatory diseases |
How Is negative regulation of cytokine production involved in inflammatory response Regulated?
The negative regulation of cytokine production involved in inflammatory response is itself tightly regulated at multiple levels. Transcriptional control involves anti-inflammatory transcription factors such as Nrf2, which is activated by itaconate-mediated KEAP1 alkylation. Post-transcriptional mechanisms include mRNA stability and microRNA-mediated silencing. Post-translational modifications such as S-persulfidation can directly modify signaling proteins to dampen cytokine production. Additionally, inhibitory receptors like IL-1R2 and CD44c provide cell-surface checkpoints that limit cytokine output. Inflammasome inhibition by proteins such as A20, SOCS1, and IRAK-M further reinforces the negative regulation. This multilayered regulation ensures that inflammation is resolved appropriately without compromising host defense.
negative regulation of cytokine production involved in inflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL37 | Asthma, inflammatory bowel disease | IL-37 overexpression in mouse models of asthma; CRISPR knock-in of human IL37 |
| KEAP1 | Chronic inflammation, cancer | KEAP1 knockout macrophages; itaconate treatment |
| IL1R2 | Trained immunity, inflammatory disorders | IL-1R2 knockout zebrafish; overexpression in teleost |
| CD44c | Viral and bacterial infection | CD44c knockout fish; infection challenge |
| NLRP3 | Autoinflammatory syndromes, gout | NLRP3 knockout mice; inflammasome inhibition assays |
Chronic inflammatory diseases
Dysregulation of GO:1900016 contributes to chronic inflammatory diseases such as periodontitis, where periodontal ligament cells produce excessive pro-inflammatory cytokines. Similarly, in asthma, insufficient negative regulation by IL-37 leads to persistent airway inflammation. Targeting these pathways could restore balance and reduce tissue damage.
Autoinflammatory and autoimmune disorders
Mutations or deficiencies in negative regulators of inflammasomes, such as A20 or IL-1RA, cause autoinflammatory diseases characterized by uncontrolled cytokine production. Understanding GO:1900016 provides a framework for diagnosing and treating these conditions by enhancing negative regulatory mechanisms.
Cytokine storms and acute inflammation
In severe infections and cytokine storms, the negative regulation of cytokine production is overwhelmed, leading to systemic inflammation and organ failure. Strategies to boost negative regulators, such as itaconate or IL-37, are being explored to mitigate cytokine storms.
Infectious diseases and host defense
Pathogens can exploit negative regulatory pathways to suppress host immunity, as seen with CD44c in piscine viral and bacterial infections. Conversely, excessive negative regulation may impair pathogen clearance, highlighting the need for balanced control.
From negative regulation of cytokine production involved in inflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate cytokine production during inflammation? | CRISPR knockout in macrophage cell lines (e.g., THP-1, RAW264.7) followed by LPS stimulation and cytokine profiling |
| Does a specific point mutation in a negative regulator alter its function? | CRISPR point mutation knock-in in primary immune cells or cell lines |
| Can overexpression of an anti-inflammatory gene suppress cytokine production? | Lentiviral overexpression of IL37 or IL1R2 in inflammatory cell models |
| What is the role of metabolic regulators in negative regulation? | Metabolite supplementation (e.g., itaconate) in wild-type and KEAP1 knockout cells |
| How does S-persulfidation affect cytokine production? | CRISPR knockout of persulfidation enzymes followed by macrophage activation |
| Can we identify novel negative regulators via genome-wide screens? | CRISPR library screening in activated macrophages with cytokine readouts |
How to Study the negative regulation of cytokine production involved in inflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Concentration of specific cytokines in supernatants | Quantifying negative regulation after LPS stimulation |
| Luminex multiplex assay | Multiple cytokine levels simultaneously | Profiling inflammatory and anti-inflammatory cytokines in disease models |
| CRISPR knockout screening | Gene essentiality for cytokine production | Identifying novel negative regulators in macrophages |
| RNA-seq | Global transcriptional changes | Assessing anti-inflammatory gene expression programs |
| Proteomics (LC-MS/MS) | Protein abundance and modifications | Detecting S-persulfidation and ubiquitination events |
| Western blot | Protein expression and phosphorylation | Validating signaling changes in negative regulation |
| Flow cytometry | Intracellular cytokine staining and surface markers | Single-cell analysis of cytokine production in immune subsets |
| Reporter assays | Promoter activity of cytokine genes | Testing transcriptional repression by negative regulators |
Cytokine profiling assays
ELISA, Luminex, or cytokine arrays are used to measure the production of pro- and anti-inflammatory cytokines in cell culture supernatants or serum. These methods are essential to quantify the output of GO:1900016 and are widely used in macrophage and dendritic cell studies.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate cytokine production. Cells are stimulated with inflammatory triggers (e.g., LPS) and cytokine levels are measured, allowing unbiased discovery of regulators within GO:1900016.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can detect modifications such as S-persulfidation and ubiquitination on key signaling proteins. These approaches reveal how post-translational changes contribute to the negative regulation of cytokine production.
Transcriptional and epigenetic profiling
RNA-seq and ATAC-seq are used to assess changes in gene expression and chromatin accessibility upon negative regulatory signals. These methods help define the transcriptional networks that suppress cytokine genes during inflammation.
How CRISPR Can Be Used to Study GO:1900016 negative regulation of cytokine production involved in inflammatory response
Knockout
CRISPR knockout of candidate negative regulators (e.g., IL37, KEAP1, IL1R2) in immune cell lines or primary cells allows researchers to test whether loss of function increases cytokine production during inflammation. This approach directly validates the role of genes in GO:1900016.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes (e.g., in KEAP1 cysteine residues) to dissect the precise molecular mechanisms by which a protein negatively regulates cytokine production. This is particularly useful for studying post-translational modification sites.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or human orthologs into model organisms or cell lines enables tracking of negative regulator expression, localization, and interaction partners. This helps define the spatiotemporal dynamics of GO:1900016.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of anti-inflammatory genes such as IL37 or IL1R2 can enhance negative regulation and suppress cytokine production. This strategy is used to test therapeutic potential and to study downstream effects.
How EDITGENE Supports negative regulation of cytokine production involved in inflammatory response Research
Researchers studying negative regulation of cytokine production involved in inflammatory response-related genes often need to determine whether a candidate gene is causally involved in restraining inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to precise point mutations and library screens.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cytokine production involved in inflammatory response research.
Frequently Asked Questions About negative regulation of cytokine production involved in inflammatory response
What is GO:1900016?
GO:1900016 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production involved in inflammatory response.
What genes are involved in negative regulation of cytokine production involved in inflammatory response?
Key genes include IL37, KEAP1, NFE2L2, IL1R2, CD44c, NLRP3, A20, SOCS1, and IL-10, among others.
Why is negative regulation of cytokine production important?
It prevents excessive inflammation and tissue damage, and its failure contributes to chronic inflammatory and autoimmune diseases.
How does itaconate regulate cytokine production?
Itaconate alkylates KEAP1, activating Nrf2, which then suppresses pro-inflammatory cytokine production.
What is the role of IL-37 in inflammation?
IL-37 is an anti-inflammatory cytokine that suppresses pro-inflammatory cytokine production and has therapeutic potential in asthma.
How can CRISPR be used to study GO:1900016?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of genes that negatively regulate cytokine production.
What diseases are associated with defective negative regulation of cytokines?
Periodontitis, asthma, autoinflammatory syndromes, and cytokine storms are linked to impaired negative regulation.
What methods measure negative regulation of cytokine production?
ELISA, Luminex, RNA-seq, proteomics, and CRISPR screens are commonly used to quantify and dissect this process.
Can negative regulation of cytokines be targeted therapeutically?
Yes, enhancing negative regulators such as IL-37 or itaconate pathways is a promising anti-inflammatory strategy.
What is the difference between GO:1900016 and general cytokine regulation?
GO:1900016 is specifically restricted to cytokine production involved in the inflammatory response, whereas general regulation may apply to other contexts.
Conclusion
GO:1900016, negative regulation of cytokine production involved in inflammatory response, is a fundamental biological process that safeguards against excessive inflammation. Its mechanisms span anti-inflammatory cytokines, metabolic checkpoints, post-translational modifications, and inhibitory receptors. Dysregulation of this process underlies numerous chronic inflammatory and autoimmune diseases, making it a rich area for therapeutic intervention. Continued research using CRISPR models and multi-omics approaches will uncover new regulators and translate them into clinical benefit.
References
- 1. Mills EL et al.. 2018. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.. Nature 556(7699):113-117 PMID: 29590092
- 2. Nilsson BO. 2021. Mechanisms involved in regulation of periodontal ligament cell production of pro-inflammatory cytokines: Implications in periodontitis.. J Periodontal Res 56(2):249-255 PMID: 33305420
- 3. Salti T et al.. 2024. Widespread S-persulfidation in activated macrophages as a protective mechanism against oxidative-inflammatory stress.. Redox Biol 72:103125 PMID: 38574432
- 4. Cui S et al.. 2025. Characterization of type 2 interleukin-1 receptor (IL-1R2) as an inhibitory regulator of trained immunity in teleost.. Fish Shellfish Immunol 163:110429 PMID: 40398502
- 5. Cao L et al.. 2019. The negative regulation of piscine CD44c in viral and bacterial infection.. Dev Comp Immunol 96:135-143 PMID: 30885554
- 6. Slifka MK et al.. 2000. Clinical implications of dysregulated cytokine production.. J Mol Med (Berl) 78(2):74-80 PMID: 10794542
- 7. Pedraza-Alva G et al.. 2015. Negative regulation of the inflammasome: keeping inflammation under control.. Immunol Rev 265(1):231-57 PMID: 25879297
- 8. Zhang L et al.. 2017. The potential of interleukin-37 as an effective therapeutic agent in asthma.. Respir Res 18(1):192 PMID: 29137646
